and Human Services (HHS)
EXPIRED
|
Participating Organization(s)
|
National Institutes of Health (NIH) |
|
National Cancer Institute (NCI) |
|
|
Funding Opportunity Title
|
Lasker Clinical Research Scholars Program (SI2) |
|
Activity Code
|
SI2 Intramural Clinical Research Scholar Award |
|
Announcement Type
|
New |
|
Related Notices
|
NOT-OD-11-030 Pre-solicitation Announcement: The Lasker Clinical Research Scholars Program |
|
Funding Opportunity Announcement (FOA) Number
|
RFA-OD-11-001 |
|
Companion FOA
|
None |
|
Catalog of Federal Domestic Assistance (CFDA) Number(s)
|
93.140 |
|
FOA Purpose
|
This FOA solicits applications for the Lasker Clinical Research Scholars Program, for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities, and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will be eligible to apply for up to 5 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program. |
|
Posted Date
|
February 2, 2011 |
|
Open Date (Earliest Submission Date)
|
Not Applicable |
|
Letter of Intent Due Date
|
March 4, 2011 |
|
Application Due Date(s)
|
April 4, 2011 |
|
AIDS Application Due Date(s)
|
Not Applicable |
|
Scientific Merit Review
|
June/July, 2011 |
|
Advisory Council Review
|
September, 2011 |
|
Earliest Start Date(s)
|
September 2011 |
|
Expiration Date
|
April 5, 2011 |
|
Due Dates for E.O. 12372
|
Not Applicable |
Required Application Instructions
It is critical that applicants follow the instructions in the PHS 398 Application Guide (http://grants.nih.gov/grants/funding/phs398/phs398.html) except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions described in this FOA. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
This program will address the clinical research mission of the National Institutes of Health (NIH) and will lead to better treatments for disease and to improvements in human health. The NIH funds research and research training at extramural institutions, as well as within the NIH Intramural Research Program (IRP) to address this goal. However, these efforts can be hindered by barriers to clinical and translational research. Such barriers include limited research time for clinical investigators, increases in the length of time to independent careers, and access to hospital facilities and patient enrollments.
In an effort to address those barriers, the NIH has created the Lasker Clinical Research Scholars (Lasker Scholars) program that will offer applicants the opportunity to compete for a unique combination of intramural and extramural resources for clinical research. The program will support a small number of exceptional clinical researchers in the early stages of their careers to promote their development to fully independent scientists. The program combines a period of research experience as a tenure-track Principal Investigator in the NIH Intramural Research Program (IRP) with an opportunity for additional years of independent financial support, either within the IRP or at an extramural research institution.
The program honors the contributions of Mary and Albert Lasker to the National Institutes of Health and to the overall biomedical community.
The Lasker Scholars program aims to support successful candidates in two phases. Applicants will respond to this Funding Opportunity Announcement (FOA) for an initial period of support through a position in the NIH Intramural Research Program. Selected scholars who successfully complete the initial phase will be able to either remain within the IRP or apply for extramural grant funding in the second phase. The first phase will support scholars in the IRP for up to 5 years, with the possibility of an extension for an additional 2 years. Successful applicants for the Lasker Scholars Program will be appointed as independent tenure-track investigators within an NIH Institute or Center, a process that includes being hired as a full time employee at the NIH and completing the procedures required of new Federal government employees. The IRP will provide space, research expenses, full salary, and Federal employee benefits. Scholars will develop independent research activities over the course of their stay in the IRP, and will be formally reviewed by a panel of senior extramural investigators every 2-4 years to evaluate their research progress.
Upon successfully completing the initial IRP phase of the program, the Lasker Scholar will be eligible for two options in the second phase:
Option 1. Remain in the IRP with continued intramural funding and progression to tenured senior investigator status, if consistent with formal reviews and assessments. Retention in the IRP will be dependent on the development of a mutual agreement between the Scholar and the IRP. Tenure at the NIH requires evaluation and approval by the NIH Deputy Director for Intramural Research.
Option 2. Scholars who successfully complete at least five years in the first phase of the program will be eligible to compete for an extramural research grant in the second phase of the program as an independent researcher. The second phase of the Lasker Scholars Program involves competition for a grant that can provide direct costs of up to $500,000/year (plus applicable Facilities and Administration (F&A) costs) for up to 5 years at an extramural institution. Scholars who choose to leave the Lasker program before completing 5 years of research in the IRP will not be eligible to compete for the Lasker Scholars Grant but will be eligible to compete for other extramural NIH research grants as announced in the NIH Guide for Grants and Contracts.
The NIH expects to make at least 3 Lasker Scholar awards in the first year of the program, ultimately reaching a steady-state of 20-30 active awardees.
The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences research workforce. The NIH expects all of its efforts to diversify the workforce to lead to the recruitment of the most talented researchers; to improve the quality of the education and training for all researchers; to balance and broaden national perspectives in setting research priorities; to improve the ability to recruit subjects from diverse backgrounds into clinical research protocols; and to improve the Nation's capacity to address and eliminate health disparities. The NIH encourages applications from talented researchers from diverse backgrounds that may be underrepresented in biomedical research, including underrepresented racial and ethnic groups, persons with disabilities and women for participation in all NIH-funded research opportunities.
Participating NIH Institutes and Centers, and their preferred areas of clinical research interest, are given here. Applicants are encouraged to discuss their proposed research with the Institute/Center contact person given in Section VII to determine the suitability of their research program to this initiative.
National Cancer Institute
Medical oncology, pediatric hematology-oncology, radiation oncology, surgical oncology, pathology, neuro-oncology, urology and dermatology. Specific areas within these categories include genitourinary oncology, lymphoma/myeloma, neuron-oncology, immunotherapy, breast cancer, sarcoma, molecular diagnostics, and functional imaging.
Translational and clinical epidemiology/genetics of cancer
National Heart, Lung, and Blood Institute
Cardiovascular blood and pulmonary research: regenerative medicine, pediatric and developmental biology
Cardiovascular research: heart failure, electrophysiology, interventional therapeutics
Blood research: chronic myeloproliferative disorders, hemeostasis, benign hematology
Pulmonary research: pulmonary interstitial disease, pulmonary hypertension
National Human Genome Research Institute
Genomic medicine
National Institute of Allergy and Infectious Diseases
Infectious diseases including TB, neglected tropical diseases, malaria, and hepatitis
Eunice Kennedy Shriver National Institute of Child Health and Human Development Metabolic diseases and neurogenetics; bone growth and skeletal dysplasia; endocrine oncology; regenerative medicine and stem cell biology; perinatal medicine; reproductive medicine; rehabilitative medicine
National Institute on Dental and Craniofacial Research
Oral and craniofacial function and dysfunction
National Institute on Drug Abuse
Development of medications for treatment of diseases/disorders of addiction
National Institute of Mental Health
Clinical neuroscience relevant to mental illness
National Institute of Neurological Disorders and Stroke
Stroke, movement disorders, neurogenetics, neuroimmunology, neurovirology
National Institute of Nursing Research
Molecular-genetic mechanisms that contribute to symptoms biology; discovery of novel mechanisms and development of investigational strategies for fatigue, chemotherapy-induced and diabetic peripheral neuropathy, chronic abdominal pain, fibromyalgia, traumatic brain injury, and sickle cell disease pain; integrative medicine
National Institutes of Health Clinical Center
Traumatic brain injury, imaging sciences (including PET and novel ligand development), cellular therapies in transfusion medicine, use of mass spectroscopy in clinical chemistry and microbiological diagnosis
|
Funding Instrument
|
Appointment |
|
Application Types Allowed
|
New |
|
Funds Available and Anticipated Number of Awards
|
It is anticipated that at least 3 awards will be made this year. Over time, the program is expected to achieve a steady state of approximately 20-30 scholars. |
|
Award Budget
|
During the first phase in the NIH Intramural Research Program, the amount of research support will vary, depending upon the specific research program of each Scholar. Funds will be provided for full salary, research expenses, and fringe benefits. For the second phase, scholars who remain in the IRP as independent, tenured senior investigators will continue to receive full salary, research expenses and fringe benefits. Scholars who successfully transition to an independent position outside the IRP will be eligible to apply for extramural funding. Awards will be up to $500,000 per year in applicable direct costs. |
|
Award Project Period
|
The initial phase of research in the IRP is for 5 years with the possibility of a 2 year extension. The extramural phase of the program is for up to 5 years. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Applications will be submitted directly by the individual PI, not from an organization.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Eligible applicants include physicians and dentists (including MD, MD/PhD, DO, DDS, DMD, RN/PhD, or equivalent clinical doctoral degree from an accredited domestic or foreign institution) and must have a professional license to practice in the U.S. The program is intended for investigators at the early stages of their careers. At the time the application for the initial IRP phase is submitted, applicants must be no more than 6 years from completion of their core residency training. Applicants will generally have completed or be completing a post-residency clinical fellowship, and will have demonstrated sufficient patient-oriented research experience to qualify for a tenure-track level appointment. Applicants do not have to be US citizens or permanent residents, although selected Scholars must qualify for and maintain appropriate visa/residency status throughout the program.
In order to receive the extramural award in the second phase of the program, the candidate must successfully compete and have obtained a full-time appointment at a U.S. academic institution.
The applicant must complete the following registrations as described in the PHS398 Application Guide to be eligible to apply for or receive an award. Applicants must have a valid Dun and Bradstreet Universal Numbering System (DUNS) number in order to begin each of the following registrations.
All Program Directors/Principal Investigators (PD/PIs) must also work with their institutional officials to register with the eRA Commons.
All registrations must be completed by the application due date. Applicant are strongly encouraged to start the registration process at least four (4) weeks prior to the application due date.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Eligible individuals may submit only one application in response to this FOA. Candidates who remain eligible are permitted to develop a new application in response to a reissuance of this FOA.
NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial peer review unless the applicant withdraws the pending application. NIH will not accept any application that is essentially the same as one already reviewed.
Applicants are required to prepare applications according to the current PHS 398 application forms in accordance with the PHS 398 Application Guide.
It is critical that applicants follow the instructions in the PHS398 Application Guide, except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed research
Name, address, and telephone number of the PD(s)/PI(s)
Names of other key personnel
Participating institutions
Number and title of this funding opportunity
The letter of intent should be sent to:
Syed M. Quadri, Ph.D.Chief, Oncology Translational Clinical
IRG
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Rm 6210
Bethesda, MD 20892
Tel: 301 435-1211
Fax: 301 480-0287
Email: quadris@csr.nih.gov
Applications must be prepared using the PHS 398 research
grant application forms and instructions for preparing a research grant
application. Submit a signed, typewritten original of the application,
including the checklist, and five signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
Page Limitations
All page limitations described in the PHS 398 Application Guide and the Table of Page Limits must be followed.
Research Plan
All instructions in the PHS398 Application Guide must be followed, with the following additional instructions:
Specific Aims (1 page maximum). State concisely the goals of the proposed research and summarize the expected outcome(s), including the impact that the results of the proposed research will have on human health.
Research Strategy (12 pages maximum).
(a) Significance Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses. Explain how the proposed project will improve the field, as well as the effect on human health. Describe how the field will be changed if the proposed aims are achieved.
(b) Innovation Explain how the application challenges and seeks to shift current clinical practice or research paradigms. Describe any novel theoretical concepts, approaches or methodologies, instrumentation or intervention(s) to be developed or used, and any advantage over existing methodologies, instrumentation, or intervention(s). Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation or interventions.
(c) Approach Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed and interpreted as well as any resource sharing plans as appropriate. Discuss potential problems, alternative strategies, and benchmarks for success anticipated to achieve the aims. If the project is in the early stages of development, describe any strategy to establish feasibility, and address the management of any high risk aspects of the proposed work. Include preliminary data, if appropriate. Point out any procedures, situations, or materials that may be hazardous to personnel and precautions to be exercised.
Literature Citations. Provide a bibliography of any references cited in the Research Plan.
Special Instructions
All application instructions outlined in the Instructions for PHS 398, Rev. 06/2009 (http://grants.nih.gov/grants/funding/phs398/phs398.html) are to be followed, with the following exceptions, which are specific requirements for the Lasker Clinical Research Scholars Program
PHS 398 COVER LETTER
PHS 398 FORM PAGE 1
Item number 2. Indicate Yes, Number (RFA-OD-11-001), Lasker Clinical Research Scholars Program.
Item numbers 6 through 10. Leave blank
Item number 11. Enter your DUNS number
Item Numbers 12 through 14. Leave blank, applications will be submitted directly from applicants.
PHS 398 PROJECT/PERFORMANCE SITE(S) (FORM PAGE 2)
Leave blank
PHS 398 DETAILED BUDGET FOR INITIAL BUDGET PERIOD (FORM PAGE 4)
Leave blank
PHS 398 BUDGET FOR ENTIRE PROPOSED BUDGET PERIOD (FORM PAGE 5)
Leave blank
PHS 398 RESOURCES
Rather than indicate the resources available, describe resources and major equipment that will be required to conduct the proposed research
PHS 398 CHECKLIST
Type of application. Check NEW
1. Program Income. Leave
blank
2.
Assurances/Certifications. Leave blank
3. Facilities and Administrative costs (F&A)/Indirect Costs. Leave blank
Resource Sharing Plans will be evaluated for compliance with NIH Intramural policies after an appointment is made.
Appendix
Do not use the appendix to circumvent page limits. Follow all instructions for the Appendix (please note all format requirements) as described in the PHS398 Application Guide.
3. Submission Dates and
Times
Part I. Overview Information contains information about Key Dates.
Information on the process of receipt and determining if
your application is considered on-time is described in detail in the PHS398
Application Guide.
Applicants may track the status of the application in the eRA Commons, NIH’s electronic system for grants
administration.
This initiative is not subject to intergovernmental review.
Not applicable.
Applications must be received on or before the due dates in Part I. Overview Information. If an
application is received after that date, it will not be reviewed.
For application to the initial phase of the program, do not enter any amount for the budget requested. Applicants accepted into the program will be funded by the NIH Intramural Research Program. Successful Lasker Scholars who later apply for the extramural funds will request direct costs and F&A costs at that time.
Letters of reference are an important component of the Lasker Clinical Research Scholar application. Applicants should arrange to have four letters of reference submitted on their behalf. Applications that are missing letters of reference will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of letters to ensure that the letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their eRA Commons accounts.
Letters may be submitted beginning February 15, 2011 and must be submitted no later than 5:00 p.m. (EST) on April 4, 2011.
To submit a letter of reference, the referee will need the following information:
Letters of reference are confidential to the extent permitted by law. E-mail confirmations will be sent to both the applicant and the referee. Note: Since e-mail can be unreliable, it is the applicant s responsibility to check the status of his/her letters of reference periodically in the Commons.
Letters may be submitted to the Commons at (https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new) beginning February 15, 2011, and must be submitted no later than 5:00 p.m. (EST), April 4, 2011. Late letters will not be accepted and applications missing letters of reference may not be reviewed.
The applicant’s name should be placed at the top of the letter. Although signatures are not required, the letter must include a signature block with the referee’s full name, title, institution, and contact information.
In two pages or less, describe the applicant’s qualities that support the applicant’s claim to possess the scientific, leadership and management skills necessary to conduct successful, independent clinical research. When possible, give specific examples that illustrate these qualities.
Note: The letter submission page can be accessed without signing into the Commons, and referees do not need to be registered in the Commons. Referees must provide the applicant’s Commons User Name (User ID) and the other information below:
REFEREE INFORMATION (the individual providing the letter of reference):
APPLICANT INFORMATION (applicants must send this information to their referees):
E-mail confirmations will be sent to both the applicant and the referee following submission of the letter.
Generally, Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, Genome Wide Association Studies (GWAS) Sharing Plan) are expected, Resource Sharing Plans will be evaluated after an appointment is made.
Only the review criteria described below will be considered
in the review process. As part of the NIH mission,
all applications submitted to the NIH in support of biomedical and behavioral
research are evaluated for scientific and technical merit through the NIH peer
review system.
Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the clinical research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator
Is the clinical researcher well suited to the project? Has the candidate demonstrated appropriate experience, training, and the skills to conduct innovative clinical research? Do the letters of reference indicate that the candidate has the research and leadership skills to conduct independent research?
Innovation
Does the application challenge and seek to shift current clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project?
Are potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development, will the
strategy establish feasibility and will particularly risky aspects be
managed?
Are the plans for 1) protection of human subjects from research risks, and 2)
inclusion of minorities and members of both sexes/genders, as well as the
inclusion of children, justified in terms of the scientific goals and research
strategy proposed?
Environment
Has the applicant identified the resources and major equipment that will be needed to conduct the proposed research?
The most outstanding applications, as determined by peer review at CSR, will be further evaluated by a panel of Intramural Research Program senior investigators. A subset of candidates will be invited for an interview and seminar at the Bethesda NIH campus. The IRP panel will additionally consider the following review criteria:
Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements of the NIH Intramural Research Program?
As applicable for the project proposed, CSR reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact/priority score, but will not give separate scores for these items.
Protections for Human Subjects
Protections for Human Subjects will be evaluated after an appointment is made, and as with all research involving human subjects conducted within the IRP, will be subject to 45 CFR Part 46. Reviewers should describe any concerns at the time of review.
Inclusion of Women, Minorities, and Children
Inclusion of Women, Minorities, and Children will be evaluated after an appointment is made. Reviewers should describe any concerns at the time of review.
Vertebrate Animals
Vertebrate Animals will be evaluated after an appointment is made. Reviewers should describe any concerns at the time of review.
Biohazards
Biohazards will be evaluated after an appointment is made. Reviewers should describe any concerns at the time of review.
Resubmissions
Resubmissions are not allowed.
Renewals
Not applicable
Revisions
Not applicable.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact/priority score.
Select Agent Research
Select Agent Research will be evaluated after an appointment is made. Reviewers should describe any concerns at the time of review.
Resource Sharing Plans
Resource Sharing Plans will be evaluated after an appointment is made. Reviewers should describe any concerns at the time of review.
Budget and Period of Support
Not applicable.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (assignments will be shown in the eRA Commons) using the stated review criteria.
As part of the scientific peer review, all applications will:
Following initial peer review, applications will be reviewed by a panel of Intramural Research Program senior investigators to evaluate the appropriateness of the proposed research for the IRP. Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements of the NIH Intramural Research Program?
Select candidates will be invited to the NIH campus for an interview. Applicants who are identified to progress to the interview process will be asked to provide additional information that will be used to establish the candidates eligibility and suitability for hire. The applicant will receive a package of additional documents to complete if selected to proceed to this phase of the interview process.
Applications will be assigned to the appropriate NIH Institute or Center on the basis of established PHS referral guidelines and the research topics shown in Part 2, Section I of this FOA . Applications will compete for available funds with all other recommended applications submitted in response to this FOA . Recommended applications will receive another level of review by the appropriate national Advisory Council or Board of the selecting Institute or Center. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
Selected Scholars will be notified by the Scientific Director of the host NIH Institute or Center, and will receive a formal Notice of Employment from the NIH Human Resources Office. Lasker Scholars are appointed under excepted service. These appointments will be made under Title 42 (f) or (g). For more details on the hiring process, pay scales, and benefits, see http://hr.od.nih.gov/benefits/default.htm.
Selected Scholars will be appointed as tenure-track investigators in the NIH Intramural Research Program. Tenure-track investigators receive independent resources (staff, space, and budget), and receive mentoring from their Lab or Branch Chief, and from the Scientific Director of their Institute or Center. Additional information concerning the philosophy and practices for IRP tenure-track investigators can be found at http://sourcebook.od.nih.gov/prof-desig/ttiphilosophy.htm and at http://sourcebook.od.nih.gov/prof-desig/investigator.
During the Intramural Research Program phase, scholars will submit an annual research report for each supported project, according to the standard procedures for IRP Investigators (described at http://sourcebook.od.nih.gov/sci-prgms/annualZ01.htm). Annual reports are maintained in a searchable database at http://intramural.nih.gov/search/index.taf?_UserReference=15E8D6CB6106892A4CC5FDA6.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone 301-710-0267
TTY 301-451-5936
Email: GrantsInfo@nih.gov
eRA Commons Help Desk(Questions regarding eRA Commons
registration, tracking application status, post submission issues)
Phone: 301-402-7469 or 866-504-9552 (Toll Free)
TTY: 301-451-5939
Email: commons@od.nih.gov
Charles R. Dearolf, Ph.D.
Assistant Director for Intramural Research
National Institutes of Health
Building 1, Room 152
Bethesda, MD 20892
email: LaskerScholar@nih.gov
Information can also be found at the Lasker Scholar website, http://www.nih.gov/science/laskerscholar
Syed M. Quadri, Ph.D.
Chief, Oncology Translational Clinical IRG
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Rm 6210
Bethesda, MD 20892
Tel: 301 435-1211
Fax: 301 480-0287
Email: quadris@csr.nih.gov
National Cancer Institute (NCI)
Dr. Lee Helman (oncology)
31 Center Drive, Room 3A11
Bethesda, MD 20892
Tel: 301-496-4257
Email: helmanl@mail.nih.gov
Dr. Peggy Tucker (epidemiology)
6120 Executive Blvd.
EPS 7122, MSC 7236
Rockville, MD 20892
Tel: 301-496-4375
Email: tuckerp@mail.nih.gov
National Heart, Lung, and Blood Institute (NHLBI)
Dr. Robert Balaban
10 Center Drive CRC, Room 4-1581
Bethesda, MD 20892
Tel: 301-496-2116
Email: balabanr@nhlbi.nih.gov
National Human Genome Research Institute (NHGRI)
Dr. Dan Kastner
50 South Drive, Room 5222
Bethesda, MD 20892
Tel: 301-402-2023
Email: kastnerd@mail.nih.gov
National Institute of Allergy and Infectious Diseases (NIAID)
Dr. Kathy Zoon
33 North Drive, Room 2609G2
Bethesda, MD 20892
Tel: 301-496-3006
Email: kzoon@niaid.nih.gov
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Dr. Constantine Stratakis
10 Center Drive CRC Hatfield Clinical Research Center
Room 1-3330
Bethesda, MD 20892
Tel: 301-402-1998
Email: stratakc@mail.nih.gov
National Institute on Dental and Craniofacial Research (NIDCR)
Kevin S. Hardwick, D.D.S., M.P.H.
Chief, Research Training and Career Development Branch
6701 Democracy, Room 690
Bethesda, MD 20892
Phone: (301) 594-2765
Email: kevin.hardwick@nih.gov
Dr. Jim Melvin
10 Center Drive CRC, Room 5-2531
Bethesda, MD 20892
Tel: 301-402-1706
Email: melvinje@mail.nih.gov
National Institute on Drug Abuse (NIDA)
Dr. Antonello Bonci
Bldg BRC, Room 04A521, MSC 0000
251 Bayview Blvd.
Baltimore, MD 21224
Tel: 443-740-2463
Email: boncia@mail.nih.gov
National Institute of Mental Health (NIMH)
Dr. Maryland Pao
10 Center Drive CRC, Room 6-5340
Bethesda, MD 20892
Tel: 301-435-5770
Email: paom@mail.nih.gov
National Institute of Neurological Disorders and Stroke (NINDS)
Dr. Alan Koretsky
10 Center Drive, Magnuson Clinical Center
Room B1D728
Bethesda, MD 20892
Tel: 301-402-9659
Email: koretskya@ninds.nih.gov
National Institute of Nursing Research (NINR)
Dr. Ray Dionne
10 Center Drive CRC, Room 2-1339
Bethesda, MD 20892
Tell: 301-496-0294
Email: dionner@mail.nih.gov
National Institutes of Health Clinical Center (CC)
Dr. David Henderson
10 Center Drive CRC, Room 6-2551
Bethesda, MD 20892
Tel: 301-496-3515
Email: dhenderson@mail.cc.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of sections 201, 301 and 402 of the Public Health Service Act (42 U.S.C. 210, 241 and 282).
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||